News
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight ...
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...
The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...
In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...
What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...
What Happened: file made a significant move by purchasing 1,565 shares of Eli Lilly as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth ...
Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results